Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.59 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139133 | 0.91 | NAALAD2 (0.66) | GPR34MMEACECPA1ACE2 | |
| SCHEMBL11936643 | 0.91 | NAALAD2 (0.66) | GPR34MMEACECPA1ACE2 | |
| SCHEMBL11940476 | 0.90 | FOLH1 (0.64) | FOLH1NAALAD2ALDH1A1 | |
| SCHEMBL11941361 | 0.86 | FOLH1 (0.57) | GPR34FOLH1NAALAD2ALDH1A1 | |
| SCHEMBL13538922 | 0.82 | NAALAD2 (0.78) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL11941426 | 0.80 | NAALAD2 (0.77) | ACEFOLH1NAALAD2 | |
| SCHEMBL14116846 | 0.80 | NAALAD2 (0.77) | ACEFOLH1NAALAD2 | |
| SCHEMBL11936645 | 0.80 | FOLH1 (0.78) | FOLH1NAALAD2ALDH1A1 | |
| SCHEMBL4138612 | 0.80 | FOLH1 (0.78) | FOLH1NAALAD2ALDH1A1 | |
| SCHEMBL11941364 | 0.79 | NAALAD2 (0.61) | FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | GPR34 2183/4885MME 253/4885ACE 362/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | GPR34 2183/4885MME 253/4885ACE 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.